IFP Advisors’s Crescent Biopharma CBIO Stock Holding History

IFP Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2	Closed	-$3K	–	3942
2018 Q1	$3K	Hold	2	–	–	﹤0.01%	3370
2017 Q4	$3K	Buy	+2	New	+$2.65K	﹤0.01%	3420

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFP Advisors's CBIO Position: Q2 2018 in Review

IFP Advisors sold out of Crescent Biopharma (CBIO) in Q2 2018, closing a stake of 2 shares — an estimated $3K sold.

IFP Advisors first reported a position in CBIO in Q4 2017 and held it in 2 quarters. The position peaked at $3K in Q1 2018. 84 funds tracked by Wall St. Rank hold CBIO as of Q2 2018.

IFP Advisors reported no remaining Crescent Biopharma position as of Q2 2018 after selling out during the quarter.
IFP Advisors sold 2 Crescent Biopharma shares in Q2 2018, an estimated $3K.
IFP Advisors first reported a position in Crescent Biopharma in Q4 2017 and held it in 2 quarters.
IFP Advisors's Crescent Biopharma position peaked at $3K in Q1 2018.
84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2018.

Based on IFP Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.